Clinical Trials Sponsored by Othera Pharmaceuticals

Total 20476 results

Othera Pharmaceuticals

Completed

Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma

Ocular Hypertension | Glaucoma, Open-Angle

United States
Othera Pharmaceuticals

Terminated

Study of OT-551 Eye Drops to Prevent or Delay Progression of Nuclear Cataracts Following Vitreous Removal

Epiretinal Membrane | Macular Hole

United States
Othera Pharmaceuticals

Unknown

The OMEGA Study: Use of Eye Drops to Treat Geographic Atrophy Associated With Age-Related Macular Degeneration (Dry AMD) (OMEGA)

Age-Related Macular Degeneration

United States
Anthera Pharmaceuticals

Completed

BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration

IgA Nephropathy

Czechia, Germany, Hong Kong, Korea, Republic of, Malaysia, Philippines, Singapore, Taiwan, Thailand, United Kingdom
Anthera Pharmaceuticals

Completed

FRANCIS-ACS Trial: A Study of the Safety and Efficacy of A 002 in Subjects With Acute Coronary Syndromes (FRANCIS-ACS)

Acute Coronary Syndrome

Russian Federation, Georgia, Ukraine
Anthera Pharmaceuticals

Terminated

A Study of Varespladib Infusion in Subjects With Sickle Cell Disease. (IMPACTS-2)

Sickle Cell Disease | Vaso-occlusive Crisis

United States
Anthera Pharmaceuticals

Completed

A Trial for Subjects With Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321

Systemic Lupus Erythematosus

United States, Argentina, Brazil, Chile, Colombia, Hong Kong, India, Mexico, Peru, Philippines, Taiwan
Anthera Pharmaceuticals

Terminated

VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome (VISTA-16)

Acute Coronary Syndrome

United States, Australia, Canada, Czech Republic, Georgia, Germany, Hungary, India, Italy, Korea, Republic of, Lebanon, Netherlands, New Zealand, Poland, Russian Federation, Spain, Ukraine
Anthera Pharmaceuticals

Terminated

A Study of the Pharmacokinetics and Safety of Varespladib in Subjects With Normal or Impaired Renal Function

Renal Impairment

United States
Anthera Pharmaceuticals

Completed

Study to Assess the Metabolism and Elimination of [14C]-Labeled Varespladib Methyl in Healthy Male Subjects

Healthy Volunteers

United States
Anthera Pharmaceuticals

Completed

EASY: Extended Access to Sollpura Over Years

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States, Hungary, Israel, Poland, Spain, Czechia
Anthera Pharmaceuticals

Unknown

RESULT: Reliable, Emergent Solution Using Liprotamase Treatment

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States, Hungary, Israel, Lithuania, Poland, Spain, United Kingdom
Anthera Pharmaceuticals

Terminated

CHABLIS7.5: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis

Systemic Lupus Erythematosus

Georgia
Anthera Pharmaceuticals

Completed

CHABLIS-SC1: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus (CHABLIS-SC1)

Systemic Lupus Erythematosus

Georgia, Belarus, Brazil, Colombia, Guatemala, Hong Kong, India, Korea, Republic of, Malaysia, Mexico, Philippines, Russian Federation, Singapore, Sri Lanka, Taiwan, Thailand
Anthera Pharmaceuticals

Withdrawn

MONICA-SC: A Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in Subjects With ITP

Idiopathic Thrombocytopenic Purpura | Immune Thrombocytopenic Purpura
Anthera Pharmaceuticals

Completed

Open-Label Phase III Long-Term Safety Trial of Liprotamase (DIGEST)

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States
Anthera Pharmaceuticals

Completed

IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome

Sickle Cell Disease | Acute Chest Syndrome | Vaso-occlusive Crisis

United States
Anthera Pharmaceuticals

Completed

PLASMA Trial: A Dose-Response Study of A-002 In Subjects With Stable Coronary Artery Disease (PLASMA)

Coronary Artery Disease (CAD)

United States, Ukraine
Anthera Pharmaceuticals

Completed

SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States, Hungary, Israel, Poland, Spain, Canada, Czechia
Anthera Pharmaceuticals

Completed

SIMPLICITY: Studying Impacts on Malabsorption With Liprotamase in Cystic Fibrosis (SIMPLICITY)

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States
Anthera Pharmaceuticals

Withdrawn

CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis

Systemic Lupus Erythematosus
Anthera Pharmaceuticals

Withdrawn

BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis (BIANCA-SC)

Microscopic Polyangiitis | Granulomatosis With Polyangiitis
Anthera Pharmaceuticals

Withdrawn

BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy

IgA Nephropathy
Anthera Pharmaceuticals

Terminated

Phase III ALTU-135 CP Safety Trial (DIGEST CP)

Exocrine Pancreatic Insufficiency

United States
Anthera Pharmaceuticals

Completed

Liprotamase Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency (DIGEST)

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States
Anthera Pharmaceuticals

Completed

PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus (PEARL-SC)

Systemic Lupus Erythematosus

United States, Argentina, Brazil, Chile, Colombia, Hong Kong, India, Mexico, Peru, Philippines, Taiwan
Anthera Pharmaceuticals

Completed

PLASMA 2 Trial: Examination of Once Daily (QD) Dosing of A-002 In Subjects With Stable Coronary Artery Disease (PLASMA 2)

Coronary Artery Disease

United States
AstraZeneca
Medpace, Inc.; Omthera Pharmaceuticals, Inc

Completed

[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL (ESPRIT)

Cardiovascular Disease | Hypertriglyceridemia

United States
Anthera Pharmaceuticals
Cystic Fibrosis Foundation

Completed

Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency

Cystic Fibrosis | Pancreatic Insufficiency

United States
OxThera

Completed

Study to Evaluate the Efficacy and Safety of OxabactTM on Reduction of Urinary Oxalate in Primary Hyperoxaluria Patients (PHOENIX)

Primary Hyperoxaluria

United States
OxThera

Completed

Phase 2/3 Oxabact Study

Primary Hyperoxaluria

United States, Germany, Netherlands
OxThera

Completed

A Study to Evaluate the Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria

Primary Hyperoxaluria

France, United Kingdom, Spain, Belgium, United States, Germany, Tunisia
OxThera

Terminated

An Extension Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria (ePHex-OLE)

Hyperoxaluria, Primary

United Kingdom, Spain, Belgium, United States, Germany, Tunisia
University Health Network, Toronto
Anthera Pharmaceuticals

Completed

sPLA2 Inhibition to Decrease Enzyme Release After PCI Trial (SPIDER-PCI)

Coronary Artery Disease

Canada
Schiano, Thomas D., MD
iTherX Pharmaceuticals Inc.

Terminated

Study of Hepatitis C Virus (HCV) Entry Inhibitor in Liver Transplant Recipients With HCV Infection

Hepatitis C Infection

United States
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment

Postmenopausal Women With Advanced Breast Cancer

Japan
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Postmenopausal Women With Advanced Breast Cancer

Japan
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Postmenopausal Women With Advanced Breast Cancer

Japan
Athera Biotechnologies AB

Completed

Efficacy, Safety and Tolerability of ATH3G10 in Patients With ST-elevation Myocardial Infarction

ST Elevation Myocardial Infarction

Sweden
Mayo Clinic
OxThera

Completed

Oxazyme in Patients With Hyperoxaluria

Hyperoxaluria

United States
National Institutes of Health Clinical Center (CC)
National Eye Institute (NEI); Othera Pharmaceuticals

Completed

OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration

Age-Related Macular Degeneration | Geographic Atrophy | AMD

United States
Cothera Bioscience, Inc

Recruiting

Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma

Lymphoma, B-Cell | Lymphoma, Large B-Cell, Diffuse | Lymphatic Diseases | Burkitt Lymphoma | High-grade B-cell Lymphoma | C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma | C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma | Lymphoma, High-Grade | C-Myc Gene Rearrangement

Korea, Republic of, China
Athera Biotechnologies AB

Terminated

Phosphorylcholine PC-mAb Effects in Subjects With Elevated Lipoprotein a

Cardiovascular Diseases | Arterial Inflammation

Sweden, Netherlands
Bio-Thera Solutions

Recruiting

Assessment of Safety, Tolerability and Pharmacokinetics With BAT4706 and BAT1308 in Advanced Solid Tumors Patients

Advanced Solid Tumor

China
Bio-Thera Solutions

Not yet recruiting

A Comparative Pharmacokinetic Study to Evaluate Different Manufacturing Batches of BAT1706 Injection

Healthy Men

China
Bio-Thera Solutions

Recruiting

A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders

Neuromyelitis Optica Spectrum Disorders

China
Bio-Thera Solutions

Active, not recruiting

Assessment on Efficacy and Safety of BAT2306 and Cosentyx® in Plaque Psoriasis Patients

Plaque Psoriasis

China
Bio-Thera Solutions

Terminated

Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients

Advanced Solid Tumor

Australia
Bio-Thera Solutions

Active, not recruiting

Evaluating the Safety, Tolerability, and Pharmacokinetics of BAT1006

Advanced Solid Tumor

China
Bio-Thera Solutions

Completed

A Comparative Study of BAT1706 and EU Avastin® in Patients With Advanced Non Squamous Non Small Cell Lung Cancer

Non-squamous Non-small Cell Lung Cancer

China, Mexico, South Africa, Turkey, Ukraine

Clinical Trials Sponsored by Othera Pharmaceuticals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations